Free Trial
NASDAQ:INVO

INVO Bioscience (INVO) Stock Price, News & Analysis

INVO Bioscience logo
$0.80
+0.05 (+6.68%)
(As of 11/1/2024 ET)

About INVO Bioscience Stock (NASDAQ:INVO)

Key Stats

Today's Range
$0.75
$0.81
50-Day Range
$0.66
$1.24
52-Week Range
$0.63
$3.50
Volume
99,743 shs
Average Volume
1.59 million shs
Market Capitalization
$3.04 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
Consensus Rating
N/A

Company Overview

INVO Bioscience, Inc., together with its subsidiary, a healthcare services fertility company, provides assisted reproductive technology solutions worldwide. It offers INVOcell, a medical device that allows fertilization and early embryo development to take place in vivo within the woman's body. The company was founded in 2007 and is based in Sarasota, Florida.

Receive INVO Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for INVO Bioscience and its competitors with MarketBeat's FREE daily newsletter.

INVO Stock News Headlines

NAYA Biosciences to present insights into mode of action of NY-303
625,000% Gain
Imagine swapping your daily coffee expense for a future free of financial worries. It might seem far-fetched, but results like this are within reach with the right knowledge and timing in the altcoin market. Plus, you’ll get $10 in real Bitcoin when you stay to the end of the call and take a short quiz.
NAYA Biosciences Inc (INVO)
What Happened With Invo BioScience Stock Today?
See More Headlines

INVO Stock Analysis - Frequently Asked Questions

INVO Bioscience's stock was trading at $1.35 at the beginning of 2024. Since then, INVO stock has decreased by 40.9% and is now trading at $0.7980.
View the best growth stocks for 2024 here
.

INVO Bioscience, Inc. (NASDAQ:INVO) announced its quarterly earnings results on Wednesday, August, 14th. The company reported ($0.62) earnings per share for the quarter. The firm had revenue of $1.84 million for the quarter.

INVO Bioscience's stock reverse split on the morning of Thursday, July 27th 2023. The 1-20 reverse split was announced on Thursday, July 27th 2023. The number of shares owned by shareholders was adjusted after the closing bell on Thursday, July 27th 2023. An investor that had 100 shares of stock prior to the reverse split would have 5 shares after the split.

INVO Bioscience's top institutional shareholders include CWC Advisors LLC. (2.64%). Insiders that own company stock include Andrea Goren, Steve Shum, Michael Jos Campbell and Matthew K Szot.
View institutional ownership trends
.

Shares of INVO stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

Based on aggregate information from My MarketBeat watchlists, some other companies that INVO Bioscience investors own include NVIDIA (NVDA), NIO (NIO), Tesla (TSLA), Meta Platforms (META), Nikola (NKLA), Broadcom (AVGO) and Bilibili (BILI).

Company Calendar

Last Earnings
8/14/2024
Today
11/02/2024
Next Earnings (Estimated)
11/11/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Surgical & medical instruments
Sub-Industry
N/A
Current Symbol
NASDAQ:INVO
Fax
N/A
Employees
25
Year Founded
N/A

Profitability

Net Income
$-8,030,000.00
Net Margins
-122.79%
Pretax Margin
-122.32%

Debt

Sales & Book Value

Annual Sales
$5.77 million
Book Value
($2.06) per share

Miscellaneous

Free Float
3,769,000
Market Cap
$3.04 million
Optionable
No Data
Beta
1.43
2025 Gold Forecast: A Perfect Storm for Demand Cover

Unlock the timeless value of gold with our exclusive 2025 Gold Forecasting Report. Explore why gold remains the ultimate investment for safeguarding wealth against inflation, economic shifts, and global uncertainties. Whether you're planning for future generations or seeking a reliable asset in turbulent times, this report is your essential guide to making informed decisions.

Get This Free Report

This page (NASDAQ:INVO) was last updated on 11/2/2024 by MarketBeat.com Staff
From Our Partners